Back to MPT Database

Antiretroviral (ARV)/Levonorgestrel Long-Acting MPT Injectable

Silica hydrogel-based long-acting injectable delivering ARV and levonorgestrel for up to 6 months duration. Currently in preclinical development.

Development Stage:

Preclinical – Advanced (Pre2)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Systemic - Injectable (Subcutaneous)

Mechanism of Action:

Integrase strand-transfer inhibitor; progestin

Developer:

  • CONRAD

Funding:

  • Eastern Virginia Medical School
  • National Institutes of Health (NIH)

Funding Mechanism:

NIH: R61

Active Ingredient(s):

  • Integrase Inhibitors
  • Levonorgestrel

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database